HER2 positivity is associated with pathogenesis and worse OS in several types of cancer, including GC.38 The Km‐plot database indicated that IRF2BP2 mRNA levels were linked with worse prognosis in HER2‐positive GC patients but not in HER2‐negative GC patients, and this characteristic may help select patients who will benefit from IRF2BP2‐targeted therapy. The gene discussed is IRF2BP2; the disease is gastric cancer.